مشخصات مقاله | |
ترجمه عنوان مقاله | مطالعه داخل موجود زنده (In vivo) و خارج از موجود زنده (آزمایشگاهی) (In virto) حفاظت عصبی نانوذرات لیپیدی جامد پر شده با دی متیل فومارات |
عنوان انگلیسی مقاله | In vitro and In vivo neuroprotective study of solid lipid nanoparticles loaded with dimethyl fumarate |
انتشار | مقاله سال 2018 |
تعداد صفحات مقاله انگلیسی | 6 صفحه |
هزینه | دانلود مقاله انگلیسی رایگان میباشد. |
پایگاه داده | نشریه Asia Pharmaceutics |
نوع نگارش مقاله | مقاله پژوهشی (Research article) |
مقاله بیس | این مقاله بیس نمیباشد |
نمایه (index) | scopus – master journals |
نوع مقاله |
ISI |
فرمت مقاله انگلیسی | |
ایمپکت فاکتور(IF) |
0.263 در سال 2017 |
شاخص H_index | 14 در سال 2019 |
شاخص SJR | 0.144 در سال 2017 |
شناسه ISSN | 0973-8398 |
شاخص Quartile (چارک) | Q3 در سال 2017 |
رشته های مرتبط | پزشکی – زیست شناسی |
گرایش های مرتبط | علوم آزمایشگاهی – علوم سلولی و مولکولی |
نوع ارائه مقاله |
ژورنال |
مجله / کنفرانس | Asian Journal of Pharmaceutics |
دانشگاه | Department of Pharmacy, School of Pharmaceutical Sciences, Vishveshwarya Group of Institutions, Greater Noida, Uttar Pradesh, India |
کلمات کلیدی | مدل کوپریزون، دی متیل فومارات، اسکلروسیز چندگانه، سلول های نوروبلاست SH-SY5Y |
کلمات کلیدی انگلیسی | Cuprizone model, dimethyl fumarate, multiple sclerosis, SH-SY5Y neuroblast cells |
شناسه دیجیتال – doi | https://doi.org/10.22377/ajp.v12i01.2044 |
کد محصول | E11952 |
وضعیت ترجمه مقاله | ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید. |
دانلود رایگان مقاله | دانلود رایگان مقاله انگلیسی |
سفارش ترجمه این مقاله | سفارش ترجمه این مقاله |
بخشی از متن مقاله: |
INTRODUCTION The neurodegenerative process with damage to axons and oligodendrocytes is thought to be the cause of permanent neurological impairment and disability; this is a key feature of the disease multiple sclerosis (MS).[1,2] At present, most available MS therapies are thought to exert their effects through immunomodulatory or immunosuppressive functions.[3-5] Although these treatments are effective at inhibiting immune cell-driven inflammation and reducing the relapse rate, they are ineffective at controlling the predominantly neurodegenerative processes that occur later in the disease course.[6] Fumaric acid esters have been used since 1959 as a treatment for psoriasis.[7] Dimethyl fumarate (DMF) is currently approved by FDA as a first-line treatment for lowering relapse rates in MS.[8-11] DMF and monomethyl fumarate were able to activate the transcription factor nuclear factor-erythroid 2-related factor 2 pathways and subsequently induce the expression of antioxidant proteins.[12,13] Oxidative stress is one of the major factors in the pathogenesis of MS and is readily apparent within experimental autoimmune encephalomyelitis, a mouse model of MS, and also in MS lesions.[14] In recent years, many research has proved that new nanotechnology can be applied for the treatment and diagnosis of variety of immune-mediated diseases like MS. Solid lipid nanoparticles (SLNs) are a novel, nanocolloidal, biocompatible drug delivery systems with improved bioavailability and drug payload. These nanocolloidal systems have been recently explored for targeting central nervous system (CNS) and various neurological disorders. Taking cognizance to the challenges for neurological disorders, patient compliance, and enhanced efficacy, it was envisioned to formulate DMF loaded SLNs in an attempt to overcome these concerns. Further, the developed colloidal system was evaluated in vitro in human neuroblastoma cells and an established cuprizone animal model. |